**# 14 |** **MEDICATION PLANNER INITIATIVE Category:** Education and Treatment Adherence

**Agency:** Tulane University Health Sciences Center

**City:** Alexandria **State:** Louisiana

**Subpopulation:** MSM of Color

**Regional Group:** Louisiana

**Contact Name:** Angela Evans

**Contact Email:** [aevans@tulane.edu](mailto:aevans@tulane.edu)

**Contact Phone:** (318) 484-4801

**Evidence of Improvement:** Yes **Other Data:** N/A

**Intervention:** Designated a medication planner nurse to fill medication planners for patients, coordinating with doctors who prescribe; patients are to come once a week to pick up medication planners.

**Change Ideas:**

* Assessed patients for eligibility in medication planner initiative during clinic visit, assessing distance or transportation capabilities to pick up planner weekly, and assessing adherence and compliance troubles
* When a provider identified clients with increased viral loads due to non-compliance, they were referred to medication planner nurse
* The Licensed Practical Nurse (LPN) met clients, educated on meds, importance of adherence/compliance, and exchanged planners

**Intervention Description:**

Patients were assessed on viral load and eligibility in the medication planner initiative during clinic visits, including assessment of distance or transportation capabilities to pick up planners weekly, and adherence and compliance barriers. When a provider identified clients with increased viral loads due to non-compliance, they were referred to the medication planner nurse. The Licensed Practical Nurse (LPN) met with clients, educated them on medications and importance of adherence/compliance, and exchanged the medication planners. During this intervention, viral suppression for the MSM of color subpopulation increased from 72.16% to 86.7% from July 2018 to November 2019, respectively.

|  |  |  |  |
| --- | --- | --- | --- |
| *Do you have measurable data to demonstrate the effectiveness of this intervention?*  **Yes** | *How effective was this intervention to increase viral suppression or reduce HIV disparities? (Scale from 1-4)*  **4-Highly Effective** | *What are the start and end data points for the intervention to indicate the measurable impact?*  **N/A** | *Was this intervention tested/implemented during the Collaborative?*  **No** |
| *Is this intervention replicable across other HIV subpopulations of the Collaborative?*  **Yes** | *How do you rate the ease of replication of the intervention by other HIV providers? (Scale from 1-4)*  **4-Very Easy to Replicate** | *How much financial support do you estimate was necessary to test your intervention per patient? ($-No Additional Agency Costs; $$-1 to 49 US Dollars; $$$-50-99 US Dollars or more; $$$-100 or more US Dollars; Don't Know)*  **N/A** |  |